Dose-dependent pancreatitis risk associated with GLP-1 agonists


Here are the Dose-dependent pancreatitis risk associated with GLP-1 agonists journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Susceptible dose dependent, mirtazapine dose dependent effects, pancreatic insufficiency risk factors, mirtazapine weight gain dose dependent, risk of pancreatic cancer, dose dependent synonyms.

Dose-dependent pancreatitis risk associated with GLP-1 agonists

Objectives: Glucagon-like peptide 1 (GLP-1) receptor agonists have recently proven to be an effective treatment for type 2 diabetes mellitus (T2DM). However, these drugs are also known to carry a significant risk of drug-induced pancreatitis. The purpose of this study is to determine whether or not GLP-1-associated pancreatitis risk is dose-dependent. That is, we aim to determine whether the risk of developing pancreatitis increases with the administered dose of GLP-1 agonist or not.

Methods: We conduct a retrospective case control study using data taken from the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) database. Participants are included if they reported an adverse effect of GLP-1 agonist and reported the cumulative dose of drug administered. We measure the odds ratio of developing pancreatitis between patients who have taken a large cumulative dose of GLP-1 agonist and those with a low cumulative dose of GLP-1 agonist . The odds ratio of different GLP-1 agonists are combined via a random effects model.

Results: Patients with a high cumulative dose of GLP-1 agonist are associated with a higher risk of developing drug-induced pancreatitis associated with GLP-1 agonists, indicated by a statistically significant odds ratio. Furthermore, the odds ratio increases as the cumulative dose increases. Conclusions: GLP-1 agonists are associated with significant pancreatitis risk which increases with larger cumulative doses. © The Author(s), under exclusive licence to Tehran University of Medical Sciences 2025.

Authors : Gu J.H.; Samarneh M.

Source : Springer Science and Business Media Deutschland GmbH

Article Information

Year 2025
Type Article
DOI 10.1007/s40200-024-01552-x
ISSN 22516581
Volume 24

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here